Thomas Tan | CSO
Immunitas Therapeutics

Thomas Tan, CSO, Immunitas Therapeutics

Seng-Lai “Thomas” Tan, Ph.D., is the Chief Scientific Officer at Immunitas. Thomas brings over 20 years of therapeutic research experience in both large and small biopharmaceutical settings across different disease areas, including infectious disease, autoimmunity, and oncology. He also has broad expertise in various modalities spanning small molecules, monoclonal and bispecific antibodies, and cell-penetrating peptides. Prior to joining Immunitas, Thomas served as Chief Scientific Officer at Bicara Therapeutics. Previously, he was Vice President, Head of Immunology at Elstar Therapeutics, now Marengo Therapeutics, where he devised and implemented effective strategies to build a portfolio of differentiated and high value projects in immune-oncology. He also has led several projects toward discovery and clinical development at Forma Therapeutics and EMD Serono Research and Development Institute. Dr. Tan holds a doctorate in microbiology (viral immunology) from the University of Washington School of Medicine.


Festival of Biologics Day 2 @ 17:00

Mechanism of action of IMT-009, a monoclonal antibody targeting CD161 for immunotherapy

  • CD161 is an inhibitory receptor expressed on NK and tumor infiltrating T cells. IMT-009 blocks binding of CD161 to its ligand, CLEC2D. This reinvigorates cytotoxic T cells and NK cell function, resulting in anti-tumor efficacy.
  • Overview of Immunitas Therapeutics antibody platform
  • Mechanistic understanding of CD161 by epitope mapping and crystallography
  • Functional in vitro understanding of IMT-009 mechanism
last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers